Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Capital Expenditures (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Capital Expenditures readings, the most recent being $143000.0 for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 98.36% to $143000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.6 million, a 163.46% decrease, with the full-year FY2024 number at $5.6 million, down 38.21% from a year prior.
  • Capital Expenditures hit $143000.0 in Q4 2025 for Enanta Pharmaceuticals, up from -$1.4 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $8.7 million in Q4 2024 to a low of -$9.9 million in Q2 2025.
  • Median Capital Expenditures over the past 5 years was $630500.0 (2021), compared with a mean of $835050.0.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 6760.87% in 2022 and later plummeted 348.54% in 2024.
  • Enanta Pharmaceuticals' Capital Expenditures stood at $46000.0 in 2021, then skyrocketed by 6760.87% to $3.2 million in 2022, then tumbled by 75.06% to $787000.0 in 2023, then soared by 1011.18% to $8.7 million in 2024, then plummeted by 98.36% to $143000.0 in 2025.
  • The last three reported values for Capital Expenditures were $143000.0 (Q4 2025), -$1.4 million (Q3 2025), and -$9.9 million (Q2 2025) per Business Quant data.